Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers

Trial Profile

A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PBT 434 (Primary)
  • Indications Multiple system atrophy; Parkinson's disease
  • Focus Adverse reactions; First in man
  • Acronyms PBT434-101
  • Sponsors Alterity Therapeutics
  • Most Recent Events

    • 25 Sep 2019 Results presented in an Alterity Therapeutics Media Release.
    • 25 Sep 2019 According to an Alterity Therapeutics media release, data were presented at the 2019 International Congress of Parkinsons Disease and Movement Disorders (MDS Congress) in Nice, France.
    • 29 Jul 2019 Results published in a Alterity Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top